- Home
- GNTA vs ALXO Comparison
GNTA vs ALXO Comparison
Compare GNTA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | ALXO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 79.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | ALXO |
|---|---|---|
| Price | $1.81 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 101.1K | ★ 279.7K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.40 |
| 52 Week High | $10.00 | $2.27 |
Technical Indicators
Market Signals| Indicator | GNTA | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 50.89 |
| Support Level | $1.80 | $1.29 |
| Resistance Level | $2.07 | $1.56 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 55.29 | 51.09 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.